CBT-295

Ref. TM-T89861

Produktinformation

• Name: CBT-295

Beschreibung

CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 329.82
• Formel: C₁₈H₂₀ClN₃O
• Farbe/Form: Liquid